Lakefront Biotherapeutics NV annual report, Q4 FY2023

Filing scope and business context

The supplied filing is Galapagos NV’s Form 20-F for the fiscal year ended December 31, 2023, not Lakefront Biotherapeutics NV or a standalone 2023 fourth-quarter filing. The financial statements are prepared under IFRS in euros. Galapagos operated as a biotechnology company focused primarily on oncology and immunology, with clinical programs including GLPG5101, GLPG5201, GLPG5301 and GLPG3667.

The Jyseleca (filgotinib) business was classified as held for sale and discontinued operations at December 31, 2023. The transfer to Alfasigma closed on January 31, 2024, and comparative income statements were restated accordingly.

Financial performance and liquidity

€ millions, except per-share data20232022, restatedChange
Continuing-operations collaboration revenue239.7241.2-1%
Operating loss(88.3)(131.1)Loss narrowed 33%
Net loss from continuing operations(4.0)(71.4)Loss narrowed 94%
Net profit from discontinued operations215.7(146.6)Material improvement
Reported net profit211.7(218.0)Turned profitable
Basic and diluted EPS€3.21€(3.32)Improved
Research and development expense(241.3)(269.8)-11%
Other operating income47.336.1+31%

Continuing-operations operating margin was approximately negative 36.8%, and continuing-operations net margin was approximately negative 1.7%. The reported consolidated net margin of approximately 88.3% was substantially affected by discontinued-operations accounting and a €429.4 million catch-up recognition of filgotinib collaboration revenue.

  • Jyseleca product sales increased 28% to €112.3 million from €87.6 million.
  • Jyseleca-related collaboration revenue increased to €431.5 million from €176.4 million, primarily because the Alfasigma transaction reduced estimated remaining filgotinib development costs and accelerated revenue recognition.
  • Continuing-operations collaboration revenue consisted mainly of €230.2 million from straight-line recognition of the Gilead drug-discovery-platform consideration and €9.5 million of royalties.
  • Net cash used in operating activities was €406.0 million, compared with €500.5 million in 2022. Operational cash burn, an alternative liquidity measure, was €414.8 million versus €513.8 million.
  • Cash and cash equivalents were €166.8 million, while current financial investments were €3.52 billion, for total cash and current investments of €3.68 billion.
  • Capital expenditures were €19.3 million, down from €36.9 million. Outstanding capital-expenditure commitments were €3.9 million.
  • The company reported no financial debt. Lease liabilities totaled €9.6 million, and purchase commitments totaled €408.5 million, including €237.5 million due within one year.
  • Total equity was €2.80 billion and total liabilities were €1.56 billion at year-end.

Material changes versus the prior comparable period

  • Reported profitability reversed sharply, but primarily because of the discontinued-operations classification and the filgotinib revenue catch-up rather than recurring product economics.
  • R&D spending declined 11% overall. Spending on oncology CAR-T programs rose to €82.2 million from €30.0 million, while GLPG3667 spending rose 28% to €31.3 million. Spending on SIKi and other programs declined.
  • Sales and marketing expense in continuing operations increased 63% to €5.7 million, reflecting increased activity outside the transferred Jyseleca business; Jyseleca-related sales and marketing expense declined 21% to €113.4 million.
  • Interest income increased to €79.3 million from €18.1 million as a result of higher interest rates and the large investment portfolio.
  • Fair-value and currency gains declined to €16.3 million from €51.5 million, including a €20.5 million unrealized foreign-exchange loss in 2023 versus a €41.6 million gain in 2022.
  • Headcount decreased to 1,123 from 1,338, including approximately 400 positions transferred to Alfasigma after year-end and 121 Romainville employees transferred to NovAliX in July 2023.
  • The company recorded a €7.6 million impairment related to the Mechelen construction project and entered a five-year NovAliX collaboration requiring €73.8 million of service purchases, of which €63.9 million remained committed at year-end.

Guidance, outlook, risks and unusual items

  • Management stated that existing cash, cash equivalents and current financial investments should fund operating expenses and capital expenditures for at least 12 months, based on current assumptions. Additional capital may nevertheless be required depending on clinical progress, spending and collaboration receipts.
  • Management expects R&D and sales-and-marketing expenses to decline following the Jyseleca transfer, while investment in oncology and immunology continues. The company planned an additional reduction of approximately 100 positions.
  • Under the Alfasigma transaction, Galapagos received €50 million upfront in 2024, may receive up to €120 million of sales-based milestones and mid-single- to mid-double-digit European royalties, and must contribute up to €40 million toward Jyseleca-related development activities by June 2025.
  • Galapagos remains dependent on successful clinical development and regulatory approval of its pipeline. The CAR-T candidates face risks related to cytokine-release syndrome, neurotoxicity, secondary malignancies, manufacturing reliability, chain of identity, scalability and regulatory scrutiny.
  • GLPG5101 and GLPG5201 reported encouraging preliminary Phase 1/2 data, but the filing cautions that early-stage results may not predict later efficacy, durability, safety or regulatory outcomes. GLPG5301 entered Phase 1/2 development in relapsed/refractory multiple myeloma in December 2023.
  • GLPG3667 was in Phase 2 studies in dermatomyositis and systemic lupus erythematosus; topline results were expected in 2025 and 2026, respectively.
  • Gilead remains a major strategic and financial counterparty, owning approximately 25.35% of Galapagos at year-end and retaining rights to royalties on filgotinib sales outside Europe. The initial Gilead warrant B was scheduled to expire August 23, 2024, and a subsequent warrant required shareholder approval.
  • The company believed it was a passive foreign investment company for U.S. federal income tax purposes in 2023, which may create adverse tax consequences for certain U.S. investors.
  • No material legal proceedings were reported, and management and the auditor concluded that internal control over financial reporting was effective as of December 31, 2023.

Facts investors should verify

  • Confirm the issuer identity: the filing text is for Galapagos NV, whereas the request identifies Lakefront Biotherapeutics NV.
  • Separate recurring continuing-operations performance from the €215.7 million discontinued-operations profit and the €429.4 million filgotinib revenue catch-up.
  • Verify post-closing Alfasigma payments, the €40 million development contribution, remaining inventory exposure and the timing of potential milestones and royalties.
  • Reconcile the €3.68 billion liquidity position with the €414.8 million operational cash burn, €408.5 million purchase commitments and planned oncology investments.
  • Monitor clinical enrollment, durability and safety data for GLPG5101, GLPG5201, GLPG5301 and GLPG3667, including potential CAR-T class warnings or additional monitoring requirements.
  • Review the Gilead collaboration amendments, remaining deferred income, royalty rights, warrant terms and related-party governance disclosures.
  • Assess the impact of the approximately 100-position planned restructuring and the transfer of approximately 400 employees to Alfasigma on future operating costs.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.